TACSTD2 and neoplasm: The novel bispecific CAR-T targeting both TROP-2 and PD-L1 can release high levels of gamma interferon and interleukin-2, exhibiting good anti-tumor activity in gastric cancer xenograft models, which could further enhance the therapeutic efficacy of CAR-T in solid tumors [92].